Apalutamide, atezolizumab, binimetinib, cafilzomib, cyclophosphamide, dactinomycin, encorafenib, eribulin, etoposide, letrozole, talazoparib, tamoxifen, tegafur/gimeracil/oteracil, topotecan, trifluridine/tipiracil, vinblastine and vincristine are all now listed in the interaction checker as cancer drugs and interactions can be found with all comedications.
- Apalutamide (Erleada®) is a non-steroidal antiandrogen and is indicated for the treatment of prostate cancer.
- Atezolizumab (Tecentriq®) is a monoclonal antibody and is indicated for the treatment of non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma and breast cancer.
- Binimetinib (Mektovi®) is a MAP2K tyrosine kinase inhibitor and is indicated for the treatment of melanoma.
- Carfilzomib (Kyproliz®) is a selective proteasome inhibitor and is indicated for the treatment of multiple myeloma.
- Cyclophosphamide (Cytoxan®, Neosar®) is an alkylating agent and is indicated for the treatment of multiple myeloma, haematological malignancies, breast cancer, ovarian cancer and neuroblastoma.
- Dactinomycin (Cosmegen Lyovac®, Actinomycin D) is an anti-tumour antibiotic and is indicated for the treatment of testicular cancer, ovarian cancer, melanomas and sarcomas.
- Encorafenib (Braftovi®) is a BRAF inhibitor and is indicated for the treatment of melanoma and colorectal cancers.
- Erlubin (Halaven®) is a mitotic inhibitor and is indicated for the treatment of breast cancer and sarcomas.
- Etoposide (Etopophos®, Toposar®, Vepesid®) is a topo-isomerase inhibitor and is indicated for the treatment of lung cancer, ovarian cancer, testicular cancer, haematological malignancies and neuroblastoma.
- Letrozole (Femara®) is an aromatase inhibitor and is indicated for the treatment of hormonally-responsive breast cancer.
- Talazoparib (Talzenna®) is a PARP inhibitor and is indicated for the treatment of advanced breast cancer with BCRA mutations.
- Tamoxifen (Nolvadex®, Soltamox®) is a selective estrogen receptor modulator and is indicated for the treatment and prevention of breast cancer.
- Tegafur/Gimeracil/Oteracil (Teysuno®) is an anti-metabolite and is indicated for the treatment of gastrointestinal cancers.
- Topotecan (Hycamtin®, Potactasol®) is a topo-isomerase inhibitor and is indicated for the treatment of ovarian cancer and small cell lung cancer.
- Trifluridine/Tipiracil (Lonsurf®) is an anti-metabolite and is indicated for the treatment of gastrointestinal cancers.
- Vinblastine (Velban®, Velbe®, Alkaban-AQ) is a vinca alkaloid and is indicated for the treatment of breast cancer and testicular cancers.
- Vincristine (Mariqbo®, Oncovin®, Vincasar PFS® and Vincrex®) is a vinca alkaloid and is indicated for the treatment of breast cancer, haematological malignancies, neuroblastoma, small cell lung cancer and sarcomas.
